JP2023113751A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023113751A5 JP2023113751A5 JP2023088154A JP2023088154A JP2023113751A5 JP 2023113751 A5 JP2023113751 A5 JP 2023113751A5 JP 2023088154 A JP2023088154 A JP 2023088154A JP 2023088154 A JP2023088154 A JP 2023088154A JP 2023113751 A5 JP2023113751 A5 JP 2023113751A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- salt
- amino acids
- chloride
- anions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000009472 formulation Methods 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 14
- 238000000034 method Methods 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 6
- 150000001450 anions Chemical class 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 3
- 150000008574 D-amino acids Chemical class 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 239000008363 phosphate buffer Substances 0.000 claims 2
- -1 trifluoroacetate ion Chemical class 0.000 claims 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 1
- 150000003841 chloride salts Chemical class 0.000 claims 1
- 230000000254 damaging effect Effects 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 1
- 239000001488 sodium phosphate Substances 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462004142P | 2014-05-28 | 2014-05-28 | |
| US62/004,142 | 2014-05-28 | ||
| JP2021167771A JP7338890B2 (ja) | 2014-05-28 | 2021-10-13 | Ｔａｔ－ＮＲ２Ｂ９ｃの塩化物塩 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021167771A Division JP7338890B2 (ja) | 2014-05-28 | 2021-10-13 | Ｔａｔ－ＮＲ２Ｂ９ｃの塩化物塩 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023113751A JP2023113751A (ja) | 2023-08-16 |
| JP2023113751A5 true JP2023113751A5 (enExample) | 2023-11-30 |
Family
ID=54698210
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016569655A Expired - Fee Related JP6622222B2 (ja) | 2014-05-28 | 2015-05-28 | Ｔａｔ−ＮＲ２Ｂ９ｃの塩化物塩 |
| JP2019210223A Expired - Fee Related JP6961661B2 (ja) | 2014-05-28 | 2019-11-21 | Ｔａｔ−ＮＲ２Ｂ９ｃの塩化物塩 |
| JP2021167771A Active JP7338890B2 (ja) | 2014-05-28 | 2021-10-13 | Ｔａｔ－ＮＲ２Ｂ９ｃの塩化物塩 |
| JP2023088154A Pending JP2023113751A (ja) | 2014-05-28 | 2023-05-29 | Ｔａｔ－ＮＲ２Ｂ９ｃの塩化物塩 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016569655A Expired - Fee Related JP6622222B2 (ja) | 2014-05-28 | 2015-05-28 | Ｔａｔ−ＮＲ２Ｂ９ｃの塩化物塩 |
| JP2019210223A Expired - Fee Related JP6961661B2 (ja) | 2014-05-28 | 2019-11-21 | Ｔａｔ−ＮＲ２Ｂ９ｃの塩化物塩 |
| JP2021167771A Active JP7338890B2 (ja) | 2014-05-28 | 2021-10-13 | Ｔａｔ－ＮＲ２Ｂ９ｃの塩化物塩 |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US10206973B2 (enExample) |
| EP (2) | EP3149048B1 (enExample) |
| JP (4) | JP6622222B2 (enExample) |
| KR (3) | KR102605540B1 (enExample) |
| CN (2) | CN106661126B (enExample) |
| AU (2) | AU2015265487B2 (enExample) |
| BR (1) | BR112016027814A2 (enExample) |
| CA (1) | CA2950395C (enExample) |
| CY (1) | CY1122793T1 (enExample) |
| DK (1) | DK3149048T3 (enExample) |
| ES (2) | ES2784500T3 (enExample) |
| HR (1) | HRP20200462T1 (enExample) |
| HU (1) | HUE049074T2 (enExample) |
| IL (1) | IL249252B (enExample) |
| LT (1) | LT3149048T (enExample) |
| ME (1) | ME03790B (enExample) |
| MX (2) | MX374958B (enExample) |
| PL (1) | PL3149048T3 (enExample) |
| PT (1) | PT3149048T (enExample) |
| RS (1) | RS60625B1 (enExample) |
| RU (2) | RU2019138024A (enExample) |
| SG (2) | SG11201609911YA (enExample) |
| SI (1) | SI3149048T1 (enExample) |
| SM (1) | SMT202000307T1 (enExample) |
| UA (1) | UA123820C2 (enExample) |
| WO (1) | WO2015181756A1 (enExample) |
| ZA (1) | ZA201608843B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS53782B1 (sr) * | 2008-10-01 | 2015-06-30 | Immatics Biotechnologies Gmbh | Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera |
| US10251935B2 (en) * | 2012-11-28 | 2019-04-09 | Nono Inc. | Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| WO2015181757A1 (en) | 2014-05-28 | 2015-12-03 | Nono Inc. | Lyophilized formulation of tat-nr2b9c with acetylation scavenger |
| SMT202000307T1 (it) | 2014-05-28 | 2020-07-08 | Nono Inc | Sale cloruro di tat-nr2b9c |
| EP3919507A3 (en) | 2015-07-01 | 2022-01-12 | Immatics Biotechnologies GmbH | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| GB201511546D0 (en) * | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| GB201620611D0 (en) | 2016-12-05 | 2017-01-18 | Univ Of Lancaster | Treatment of neurological diseases |
| EP3650460A4 (en) | 2017-07-05 | 2021-03-17 | Biocells (Beijing) Biotech Co., Ltd. | PHARMACEUTICAL SALT OF A POLYPEPTID AND ITS USES |
| CN110627877A (zh) * | 2019-09-25 | 2019-12-31 | 成都奥达生物科技有限公司 | 一种psd-95抑制剂 |
| CA3166998A1 (en) * | 2020-01-09 | 2021-07-15 | Nono Inc. | Plasmin-resistant peptides for treating stroke and related conditions |
| CN111560050A (zh) * | 2020-05-25 | 2020-08-21 | 成都圣诺生物制药有限公司 | 一种Nerinetide的制备方法 |
| AU2022206444A1 (en) | 2021-01-08 | 2023-07-20 | Nono Inc. | Plasmin-resistant peptides for improved therapeutic index |
| CN113735938B (zh) * | 2021-07-30 | 2024-11-08 | 英纳氏(珠海)药业有限公司 | 一种神经保护多肽化合物及其应用 |
| EP4706670A1 (en) | 2023-04-26 | 2026-03-11 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Psd-95 domain inhibitor, and preparation method therefor and use thereof |
| WO2026012336A1 (zh) * | 2024-07-08 | 2026-01-15 | 福建盛迪医药有限公司 | 一种psd-95多肽抑制剂的可药用盐及其制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2226575C (en) * | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US7510824B2 (en) | 1999-06-02 | 2009-03-31 | Nono Inc. | Method of screening peptides useful in treating traumatic injury to the brain or spinal cord |
| US9101590B2 (en) * | 2005-07-29 | 2015-08-11 | Yale University | Defined culture conditions of human embryonic stem cells |
| US9283260B2 (en) * | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
| EP1884521A1 (en) | 2006-07-31 | 2008-02-06 | Xigen S.A. | Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins |
| DK2120987T3 (en) | 2007-03-02 | 2014-02-24 | Nono Inc | Treatment of stroke and other diseases without inhibiting N-type calcium channels |
| EP2150537A4 (en) * | 2007-06-01 | 2010-09-22 | Acologix Inc | STABLE PEPTIDE FORMULATION AT HIGH TEMPERATURE |
| US8008253B2 (en) * | 2007-07-03 | 2011-08-30 | Andrew Tasker | Treatment for anxiety |
| WO2010004003A2 (en) | 2008-07-09 | 2010-01-14 | University Of Copenhagen | Modified peptides as potent inhibitors of the psd-95/nmda receptor interaction |
| EP2440230B1 (en) * | 2009-06-10 | 2020-11-11 | NoNO Inc. | Treatment regimes for treatment of neurological disease |
| WO2012021854A2 (en) * | 2010-08-12 | 2012-02-16 | Nono, Inc. | Treatment of penetrative injury to the brain |
| UA114592C2 (uk) * | 2010-09-28 | 2017-07-10 | Ноно Інк. | Пептид nd2 та спосіб лікування неврологічного захворювання |
| PL2707014T3 (pl) * | 2011-05-13 | 2015-12-31 | Koebenhavns Univ University Of Copenhagen | Dimeryczne inhibitory PSD-95 o wysokim powinowactwie i ich zastosowanie w terapii niedokrwiennego uszkodzenia mózgu oraz leczeniu bólu |
| CN102241745A (zh) * | 2011-05-19 | 2011-11-16 | 南京医科大学 | 多肽类似物Tat-HA-NR2B9C及其制备方法和应用 |
| PT2723363T (pt) * | 2011-06-24 | 2018-11-08 | Nono Inc | Terapia de combinação para isquemia |
| US9241970B2 (en) * | 2011-12-13 | 2016-01-26 | Nono Inc. | Therapy for subarachnoid hemorrhage and ischemia |
| WO2013088382A1 (en) | 2011-12-13 | 2013-06-20 | Nono Inc. | Therapy for subarachnoid hemorrhage and ischemia |
| GB201220474D0 (en) * | 2012-11-14 | 2012-12-26 | Sagetis Biotech Sl | Polypeptides |
| KR102166374B1 (ko) | 2012-11-28 | 2020-10-15 | 노노 인코포레이티드 | Tat-nr2b9c의 동결건조된 제형 |
| US10251935B2 (en) | 2012-11-28 | 2019-04-09 | Nono Inc. | Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose |
| SMT202000307T1 (it) | 2014-05-28 | 2020-07-08 | Nono Inc | Sale cloruro di tat-nr2b9c |
| WO2015181757A1 (en) * | 2014-05-28 | 2015-12-03 | Nono Inc. | Lyophilized formulation of tat-nr2b9c with acetylation scavenger |
-
2015
- 2015-05-28 SM SM20200307T patent/SMT202000307T1/it unknown
- 2015-05-28 HR HRP20200462TT patent/HRP20200462T1/hr unknown
- 2015-05-28 PT PT157995838T patent/PT3149048T/pt unknown
- 2015-05-28 ES ES15799583T patent/ES2784500T3/es active Active
- 2015-05-28 BR BR112016027814A patent/BR112016027814A2/pt active Search and Examination
- 2015-05-28 CN CN201580028269.3A patent/CN106661126B/zh not_active Expired - Fee Related
- 2015-05-28 SG SG11201609911YA patent/SG11201609911YA/en unknown
- 2015-05-28 PL PL15799583T patent/PL3149048T3/pl unknown
- 2015-05-28 UA UAA201613470A patent/UA123820C2/uk unknown
- 2015-05-28 RU RU2019138024A patent/RU2019138024A/ru unknown
- 2015-05-28 ES ES20152821T patent/ES2974228T3/es active Active
- 2015-05-28 CA CA2950395A patent/CA2950395C/en active Active
- 2015-05-28 RU RU2016150678A patent/RU2707885C2/ru active
- 2015-05-28 EP EP15799583.8A patent/EP3149048B1/en active Active
- 2015-05-28 US US15/313,940 patent/US10206973B2/en active Active
- 2015-05-28 DK DK15799583.8T patent/DK3149048T3/da active
- 2015-05-28 WO PCT/IB2015/053995 patent/WO2015181756A1/en not_active Ceased
- 2015-05-28 HU HUE15799583A patent/HUE049074T2/hu unknown
- 2015-05-28 KR KR1020227019189A patent/KR102605540B1/ko active Active
- 2015-05-28 AU AU2015265487A patent/AU2015265487B2/en not_active Ceased
- 2015-05-28 CN CN202111366962.5A patent/CN114057895A/zh active Pending
- 2015-05-28 KR KR1020167036752A patent/KR102311038B1/ko not_active Expired - Fee Related
- 2015-05-28 LT LTEP15799583.8T patent/LT3149048T/lt unknown
- 2015-05-28 JP JP2016569655A patent/JP6622222B2/ja not_active Expired - Fee Related
- 2015-05-28 RS RS20200367A patent/RS60625B1/sr unknown
- 2015-05-28 ME MEP-2020-120A patent/ME03790B/me unknown
- 2015-05-28 MX MX2016015457A patent/MX374958B/es active IP Right Grant
- 2015-05-28 KR KR1020217031792A patent/KR102407856B1/ko not_active Expired - Fee Related
- 2015-05-28 SG SG10202001285XA patent/SG10202001285XA/en unknown
- 2015-05-28 SI SI201531132T patent/SI3149048T1/sl unknown
- 2015-05-28 EP EP20152821.3A patent/EP3757134B1/en active Active
-
2016
- 2016-11-24 MX MX2020009633A patent/MX2020009633A/es unknown
- 2016-11-28 IL IL249252A patent/IL249252B/en active IP Right Grant
- 2016-12-21 ZA ZA2016/08843A patent/ZA201608843B/en unknown
-
2018
- 2018-09-11 US US16/128,423 patent/US10758589B2/en active Active
-
2019
- 2019-11-21 JP JP2019210223A patent/JP6961661B2/ja not_active Expired - Fee Related
-
2020
- 2020-03-18 CY CY20201100251T patent/CY1122793T1/el unknown
- 2020-06-17 US US16/904,230 patent/US11266714B2/en active Active
- 2020-11-13 AU AU2020267304A patent/AU2020267304C1/en not_active Ceased
-
2021
- 2021-10-13 JP JP2021167771A patent/JP7338890B2/ja active Active
- 2021-12-08 US US17/545,995 patent/US11911438B2/en active Active
-
2023
- 2023-05-29 JP JP2023088154A patent/JP2023113751A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3533216B2 (ja) | 乳頭腫ウイルスｌ２蛋白 | |
| JP2022517399A5 (enExample) | ||
| JP2022166006A5 (enExample) | ||
| IL240686A (en) | Preparations containing cyclic peptides containing adjacent arginine residues | |
| JP2024503265A5 (enExample) | ||
| US9181303B2 (en) | Treatment of bacterial infections with cyclic antimicrobial peptides | |
| JP2021521159A5 (enExample) | ||
| JP2018512454A5 (enExample) | ||
| JP2022088521A5 (enExample) | ||
| EP1985625B1 (en) | Synthetic peptide constructs for the diagnosis and treatment of periodontitis associated with Porphyromonas gingivalis | |
| JP2023529839A5 (enExample) | ||
| JP2017517517A5 (enExample) | ||
| JP2021526505A5 (enExample) | ||
| WO2016046523A1 (en) | Use of cystamine for treating bacterial and fungal infections | |
| JP2021527647A (ja) | エキノカンジン抗真菌剤の合成 | |
| CN116406286A (zh) | 免疫调节化合物及其用于治疗和/或预防传染性疾病的用途 | |
| JP5403867B2 (ja) | 急速分散性医薬固形剤形における食用酸の使用 | |
| JP2026506447A (ja) | 呼吸器合胞体ウイルスｍＲＮＡワクチン | |
| JP2001524083A (ja) | テイコプラニン誘導体 | |
| CZ2002540A3 (cs) | Farmaceutické činidlo obsahující benzamidový derivát jako aktivní sloľku | |
| KR20220034053A (ko) | 재조합 단백질의 안정적인 제형 | |
| EP0560969B1 (fr) | Vaccin comprenant une sous-unité du récepteur de la transferrine humaine tel qu'isolé de Neisseria meningitidis | |
| AU764061B2 (en) | Use of active P40 conjugates for nasal delivery | |
| JP2021521168A5 (enExample) | ||
| JP2022515721A5 (enExample) |